Published by Iain Gilbert on 9th March 2023
(Sharecast News) - Drugmaker AstraZeneca said on Thursday that results from a phase III trial on its resectable non-small cell lung cancer treatment had shown a "significantly improved" event-free survival.
URL: http://www.digitallook.com/dl/news/story/33356865/...